These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 25519750)
1. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Jones E; Pasricha SR; Allen A; Evans P; Fisher CA; Wray K; Premawardhena A; Bandara D; Perera A; Webster C; Sturges P; Olivieri NF; St Pierre T; Armitage AE; Porter JB; Weatherall DJ; Drakesmith H Blood; 2015 Jan; 125(5):873-80. PubMed ID: 25519750 [TBL] [Abstract][Full Text] [Related]
2. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680 [TBL] [Abstract][Full Text] [Related]
3. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567 [TBL] [Abstract][Full Text] [Related]
4. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Pasricha SR; Frazer DM; Bowden DK; Anderson GJ Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728 [TBL] [Abstract][Full Text] [Related]
5. Relation of hepcidin gene expression in blood mononuclear cells with iron overload severity among β-thalassemia major patients. Ayatollahi H; Mousavi Nezhad SF; Talebpour A; Badiei Z; Nezami H Mol Biol Rep; 2020 Dec; 47(12):9353-9359. PubMed ID: 33231816 [TBL] [Abstract][Full Text] [Related]
6. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection. Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485 [TBL] [Abstract][Full Text] [Related]
7. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia. Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269 [No Abstract] [Full Text] [Related]
8. Association of alpha hemoglobin-stabilizing protein (AHSP) gene mutation and disease severity among HbE-beta thalassemia patients. Ray R; Kalantri SA; Bhattacharjee S; Biswas A; Shahab A; Biswas S; Bhattacharyya M Ann Hematol; 2019 Aug; 98(8):1827-1834. PubMed ID: 31190133 [TBL] [Abstract][Full Text] [Related]
9. New therapeutic targets in transfusion-dependent and -independent thalassemia. Cappellini MD; Motta I Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267 [TBL] [Abstract][Full Text] [Related]
10. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Schmidt PJ; Fleming MD Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273 [TBL] [Abstract][Full Text] [Related]
11. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684 [TBL] [Abstract][Full Text] [Related]
12. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665 [TBL] [Abstract][Full Text] [Related]
13. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430 [TBL] [Abstract][Full Text] [Related]
14. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Ginzburg Y; Rivella S Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301 [TBL] [Abstract][Full Text] [Related]
15. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112 [TBL] [Abstract][Full Text] [Related]
16. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia. Olivera J; Zhang V; Nemeth E; Ganz T Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275 [TBL] [Abstract][Full Text] [Related]
17. Regulation of iron homeostasis by hepatocyte TfR1 requires HFE and contributes to hepcidin suppression in β-thalassemia. Xiao X; Moschetta GA; Xu Y; Fisher AL; Alfaro-Magallanes VM; Dev S; Wang CY; Babitt JL Blood; 2023 Jan; 141(4):422-432. PubMed ID: 36322932 [TBL] [Abstract][Full Text] [Related]
18. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596 [TBL] [Abstract][Full Text] [Related]
20. Iron and hepcidin: a story of recycling and balance. Camaschella C Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]